NAV

Retosiban

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Retosiban
DrugBank Accession Number
DB11818
Background

Retosiban has been used in trials studying the treatment of Premature Labor and Obstetric Labour, Premature.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 494.592
Monoisotopic: 494.252920211
Chemical Formula
C27H34N4O5
Synonyms
  • Retosiban
External IDs
  • GSK-221149
  • GSK-221149A
  • GSK221149A

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
N-piperazineacetamides / Alpha amino acids and derivatives / Indanes / 2,5-dioxopiperazines / 2,4-disubstituted oxazoles / N-alkylpiperazines / Morpholines / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides
show 8 more
Substituents
1,4-diazinane / 2,4-disubstituted 1,3-oxazole / 2,5-dioxopiperazine / Alpha-amino acid or derivatives / Alpha-dipeptide / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Carbonyl group
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
GIE06H28OX
CAS number
820957-38-8
InChI Key
PLVGDGRBPMVYPB-FDUHJNRSSA-N
InChI
InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1
IUPAC Name
(3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-(morpholin-4-yl)-2-oxoethyl]piperazine-2,5-dione
SMILES
CC[C@H](C)[C@H]1N([C@@H](C(=O)N2CCOCC2)C2=COC(C)=N2)C(=O)[C@H](NC1=O)C1CC2=CC=CC=C2C1

References

General References
Not Available
PubChem Compound
11340891
PubChem Substance
347828165
ChemSpider
9515833
BindingDB
50372608
ChEMBL
CHEMBL429736
ZINC
ZINC000006718496
PDBe Ligand
NU2
Wikipedia
Retosiban
PDB Entries
6tpk

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentObstetric Labour, Premature1
3TerminatedTreatmentObstetric Labour, Premature2
2CompletedTreatmentObstetric Labour, Premature1
1CompletedBasic ScienceObstetric Labour, Premature1
1CompletedTreatmentObstetric Labour, Premature3
1CompletedTreatmentObstetric Labour, Premature / Premature Labour1
1TerminatedTreatmentObstetric Labour, Premature / Premature Ejaculation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.156 mg/mLALOGPS
logP2.32ALOGPS
logP1.84Chemaxon
logS-3.5ALOGPS
pKa (Strongest Acidic)10.88Chemaxon
pKa (Strongest Basic)0.44Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area104.98 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity131.33 m3·mol-1Chemaxon
Polarizability52.99 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 20:50 / Updated at February 21, 2021 18:53